Covid-T™ Clinical Development Program Initiated Regulatory Advisory Group Engaged
(World News USA)

VANCOUVER, BC, Jan. 28, 2021 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC: LMNGF) (`BioVaxys` or `Company`) is pleased to announce that it has initiated the clinical development program for Covid-T™, the Company`s novel diagnostic platform for detecting T-cell activity. The US Food and Drug Administration (`FDA`) has tentatively agreed to permit that BioVaxys can file for a pre-Emergency Use Authorization (`EUA`) for Covid-T™. Under an EUA, FDA may allow the use of unapproved medical products, or unapproved uses of approved medical products in an emergency to diagnose, treat, or prevent serious or life-threatening diseases or conditions when certain statutory criteria have...